Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2010
10/26/2010CA2404641C Oral delivery method and composition for solid medications or dietary supplements
10/26/2010CA2381229C Stabilized g-csf preparations
10/26/2010CA2351887C Psca: prostate stem cell antigen and uses thereof
10/26/2010CA2326501C Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
10/26/2010CA2199290C Transfer of molecules into the cytosol of cells
10/26/2010CA2163111C Process for the preparation of an oral solid dosage form containing diclofenac
10/26/2010CA2133323C Self-assembling polynucleotide delivery system
10/21/2010WO2010121024A2 Silicone-peroxide compositions for long-term, controlled oxygen release
10/21/2010WO2010120980A1 Methods for inhibiting angiogenesis with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
10/21/2010WO2010120755A1 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound
10/21/2010WO2010120489A2 Drug delivery system and methods of use
10/21/2010WO2010120414A2 Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
10/21/2010WO2010120389A2 Polymeric drug delivery systems and processes for producing such systems
10/21/2010WO2010120388A1 Oligomer-protein tyrosine kinase inhibitor conjugates
10/21/2010WO2010120387A1 Oligomer-protein tyrosine kinase inhibitor conjugates
10/21/2010WO2010120386A1 Oligomer-protein tyrosine kinase inhibitor conjugates
10/21/2010WO2010120266A1 Hpv particles and uses thereof
10/21/2010WO2010120021A1 Composition for photodynamic therapy comprising a macromolecular capsule
10/21/2010WO2010119994A1 Polysaccharide derivative and hydrogel thereof
10/21/2010WO2010119942A1 Levocabastine suspension type eye lotion
10/21/2010WO2010119851A1 Orally disintegrating tablet
10/21/2010WO2010119741A1 Preparation for external use
10/21/2010WO2010119389A2 Pretargeting kit, method and agents used therein
10/21/2010WO2010119386A2 A medicinal cream made using clotrimazole, fluticasone propionate, and chitosan, and a process to make the same
10/21/2010WO2010119385A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it
10/21/2010WO2010119383A1 A medicinal cream made using framycetin sulphate cream and chitosan, and a process to make it
10/21/2010WO2010119382A1 Pretargeting kit, method and agents used therein
10/21/2010WO2010119367A2 A medicinal cream made using hydrocortisone acetate and a process to make the same
10/21/2010WO2010119364A2 A medicinal cream made using neomycin sulphate, betamethasone valerate, and chitosan, and a process to make the same
10/21/2010WO2010119102A2 Pharmaceutical composition for treating dermatological autoimmune diseases
10/21/2010WO2010118985A1 Affinity material
10/21/2010WO2010118888A1 Formulation for stabilizing proteins, which is free of mammalian excipients
10/21/2010WO2010118880A1 Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions
10/21/2010WO2010118683A1 Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof
10/21/2010WO2010118639A1 Amlodipine microsphere agent, production method and use thereof
10/21/2010WO2010118516A1 Compositions for sublingual drug delivery and methods of use thereof
10/21/2010WO2010118461A1 Gel compositions for administration of pharmaceutically active compounds
10/21/2010WO2010097604A3 Guanidino-substituted bi- and polyphenyls as small molecule carriers
10/21/2010WO2010089443A3 PHARMACEUTICAL COMPOSITIONS COMPRISING TGF- β1 INHIBITOR PEPTIDES
10/21/2010WO2010083154A3 Heterofunctional segment-poly(ethylene glycol) polymers as delivery vehicles
10/21/2010WO2010078950A3 Antigens associated with endometriosis, psoriatic arthritis and psoriasis
10/21/2010WO2010074992A3 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
10/21/2010WO2010068866A3 Therapeutic particles suitable for parenteral administration and methods of making and using same
10/21/2010WO2010056065A3 Method for preparing microspheres and microspheres produced thereby
10/21/2010WO2010051530A3 Compositions and methods for delivering a substance to a biological target
10/21/2010WO2009138477A3 Epithelial delivery
10/21/2010WO2009096245A9 Pharmaceutical composition and combined agent
10/21/2010US20100268329 Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease
10/21/2010US20100267924 Phosphorus-Containing Compounds with Polymeric Chains, and Methods of Making and Using the Same
10/21/2010US20100267895 Hydrolytically Degradable Polymers and Hydrogels Made Therefrom
10/21/2010US20100267846 Molecular delivery vehicle
10/21/2010US20100267845 (meth)acrylic acid/alkyl (meth)acrylate ester copolymer and cosmetic preparation containing the same
10/21/2010US20100267844 Alkylene oxide-capped secondary alcohol alkoxylates useful as surfactants
10/21/2010US20100267843 Mixed fluoroalkyl-alkyl surfactants
10/21/2010US20100267799 Orodispersible pharmaceutical composition of perindopril
10/21/2010US20100267758 Pharmaceutical formulation
10/21/2010US20100267693 Orodispersible pharmaceutical composition of ivabradine
10/21/2010US20100267680 Use of at least one oxime derivative of cholest-4-en-3-one as antioxidants
10/21/2010US20100267664 Ophthalmic compositions containing polysaccharide-borate gelling system
10/21/2010US20100267640 Method of Attenuating Neurogenic Swelling or Neurogenic Inflammation
10/21/2010US20100267621 Antimicrobial Compounds and Formulations
10/21/2010US20100267564 Method for encapsulating oils in an aqueous medium with hase polymer emulsions, products obtained, and uses thereof
10/21/2010US20100266713 Aqueous ophthalmic compositions containing anionic therapeutic agents
10/21/2010US20100266705 Nanoparticulate megestrol formulations
10/21/2010US20100266698 Use of insulin for the treatment of cartilaginous disorders
10/21/2010US20100266697 Mixed ligand surface-modified nanoparticles
10/21/2010US20100266687 Improved tablet coating
10/21/2010US20100266683 New self emulsifying drug delivery system
10/21/2010US20100266668 Manufacturing Dissolvable Dosage Forms
10/21/2010US20100266657 Preformed drug-eluting device to be affixed to an anterior spinal plate
10/21/2010US20100266651 Emulsifier including glycerin-modified organopolysiloxanes
10/21/2010US20100266649 Gel Technology Suitable for Use in Cosmetic Compositions
10/21/2010US20100266518 Process for the preparation of odourless polyether alcohols using DMC catalysts and their use in cosmetic and/or dermatological preparations
10/21/2010US20100266492 Compounds for intracellular delivery of therapeutic moieties to nerve cells
10/21/2010CA2795906A1 Hpv particles and uses thereof
10/21/2010CA2795611A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it
10/21/2010CA2767044A1 Drug delivery system and methods of use
10/21/2010CA2759098A1 Methods and compositions for the treatment of medical conditions involving cellular programming
10/21/2010CA2758913A1 Prion free nanoparticle compositions and methods of making thereof
10/21/2010CA2758907A1 Polysaccharide derivative and hydrogel thereof
10/21/2010CA2758847A1 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound
10/21/2010CA2758820A1 Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof
10/21/2010CA2758754A1 Formulation for stabilizing proteins, which is free of mammalian excipients
10/21/2010CA2758746A1 Gel compositions for administration of pharmaceutically active compounds
10/21/2010CA2758538A1 Pharmaceutical composition for treating dermatological autoimmune diseases
10/21/2010CA2758438A1 Affinity material
10/21/2010CA2758263A1 Methods for inhibiting angiogenesis with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
10/20/2010EP2241588A1 Aqueous dispersion containing polysaccharide particulate gel and method for producing the same
10/20/2010EP2241394A1 Gold nanoparticle composition, dna chip, near infrared absorbent, drug carrier for drug delivery system (dds), coloring agent, biosensor, cosmetic, composition for in vivo diagnosis and composition for therapeutic use
10/20/2010EP2241331A2 Novel anti-DC-SIGN antibodies
10/20/2010EP2241327A1 Mixtures of Amylin and Insulin
10/20/2010EP2241326A1 Pharmaceutical compositions and methods for insulin treatment
10/20/2010EP2241320A1 Aqueous compositions containing metronidazole
10/20/2010EP2241319A1 Combination of brimonidine and timolol for topical ophthalmic use
10/20/2010EP2241314A1 Alpha-lipoic acid nanoparticle and method for producing the same
10/20/2010EP2241311A1 Timed-release pharmaceutical preparation
10/20/2010EP2241309A2 Methods for encapsulation of proteins and adjuants in microspheres
10/20/2010EP2241308A2 Method for coating fine particle with lipid membrane
10/20/2010EP2240516A1 Methods and agents for improving targeting of cd138 expressing tumor cells
10/20/2010EP2240495A1 Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
1 ... 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 ... 1712